Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens

Table 4 Univariate and multivariate Cox proportional hazards regression analyses of the overall survival of patients in the training set

Variables	Univariate analysis		Multivariate analysis
	P value	HR (95%CI)	P value	HR (95%CI)
Age, years	< 0.001c	1.08 (1.04-1.13)	< 0.001c	1.10 (1.05-1.14)
Sex
Male	0.365	1.00 (reference)	-	-
Female		0.72 (0.36-1.46)		-
Sampling position
Colon	0.671	1.00 (reference)	-	-
Rectum		0.85 (0.42-1.76)		-
Stage
II	0.017a	1.00 (reference)	0.019a	1.00 (reference)
III		3.17 (1.23-8.19)		3.13 (1.21-8.10)
ATP-TCA
Sensitive	0.100	1.00 (reference)	0.048a	1.00 (reference)
Resistant		5.31 (0.73-38.85)		7.48 (1.02-55.16)

^aP < 0.05.

^cP < 0.001.

HR: Hazard ratio; CI: Confidence interval; ATP-TCA: Adenosine triphosphate-based tumour chemotherapy sensitivity test.